BIOGEN INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B |
| Operating income | — | — | — | — | $2.8B |
| Cost of revenue | $2.4B | $2.3B | $2.5B | $2.3B | $2.1B |
| Cash from operations | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B |
| Capital expenditure | $153.8M | $153.7M | $277.0M | $240.3M | $258.1M |
| Free cash flow | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B |
| Share repurchases | — | $0 | $0 | $750.0M | $1.8B |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B |
| Total liabilities | $11.2B | $11.3B | $12.0B | $11.2B | $12.9B |
| Total debt | $6.6B | $6.6B | $7.2B | — | — |
Shares outstanding 147.6M · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.